Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 11032 results:
[ Συντάκτης(Asc)] Τίτλος Τύπος Έτος
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Athyros, V. G., Tziomalos K., Karagiannis A., Anagnostis P., & Mikhailidis D. P. (2010).  Should adipokines be considered in the choice of the treatment of obesity-related health problems?. Curr Drug Targets. 11(1), 122-35.
Athyros, V. G., & Mikhailidis D. P. (2016).  High incidence of metabolic syndrome further increases cardiovascular risk in patients with type 2 diabetes. Implications for everyday practice.. J Diabetes Complications. 30(1), 9-11.
Athyros, V. G., Tziomalos K., Katsiki N., & Mikhailidis D. P. (2014).  Novel data on the pathogenesis of atherosclerosis, treatment targets, and new therapeutic interventions in lipid-related cardiovascular risk factors.. Curr Pharm Des. 20(40), 6215-9.
Athyros, V. G., Katsiki N., & Karagiannis A. (2014).  Treating heart failure with preserved ejection fraction: statins could make the difference.. Angiology. 65(4), 328-9.
Athyros, V. G., Kakafika A. I., Wierzbicki A. S., Karagiannis A., & Mikhailidis D. P. (2009).  Targeting triglycerides in secondary prevention: should we bother?. Int J Clin Pract. 63(1), 15-8.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2010).  Lipid-lowering agents and new onset diabetes mellitus.. Expert Opin Pharmacother. 11(12), 1965-70.
Athyros, V. G., Tziomalos K., Doumas M., Sfikas G., & Karagiannis A. (2017).  The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins.. Curr Pharm Des. 23(10), 1477-1483.
Athyros, V. G., Mikhailidis D. P., Papageorgiou A. A., Didangelos T. P., Peletidou A., Kleta D., et al. (2005).  Targeting vascular risk in patients with metabolic syndrome but without diabetes.. Metabolism. 54(8), 1065-74.
Athyros, V. G., Liberopoulos E. N., Mikhailidis D. P., Papageorgiou A. A., Ganotakis E. S., Tziomalos K., et al. (2007).  Association of drinking pattern and alcohol beverage type with the prevalence of metabolic syndrome, diabetes, CHD, stroke, and peripheral arterial disease in a Mediterranean cohort.. Angiology. 58(6), 689-97.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2012).  Editorial: should chronic kidney disease be considered as a coronary heart disease equivalent?. Curr Vasc Pharmacol. 10(3), 374-7.
Athyros, V. G., Kakafika A. I., Papageorgiou A. A., Paraskevas K. I., Tziomalos K., Anagnostis P., et al. (2008).  Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study.. Curr Med Res Opin. 24(6), 1593-9.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2008).  Preventing macrovascular complications of diabetes: where do we stand with glycemic control?. Expert Opin Investig Drugs. 17(12), 1777-9.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2014).  The 2013 American College of Cardiology/American Heart Association guidelines for the treatment of dyslipidemia: mind the gaps!. Curr Med Res Opin. 30(9), 1701-5.
Athyros, V. G., Mikhailidis D. P., Kakafika A. I., Tziomalos K., & Karagiannis A. (2007).  Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?. Expert Opin Pharmacother. 8(5), 529-35.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2015).  Short-, mid-, and long-term benefits of peri-procedural high-intensity statin administration in patients undergoing percutaneous coronary intervention.. Curr Med Res Opin. 31(2), 191-5.
Athyros, V. G., Mitsiou E. K., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2010).  Concurrent blood pressure, glycemic and lipid control for the prevention of vascular complications of type II diabetes mellitus: a long overdue objective?. Curr Vasc Pharmacol. 8(1), 1-4.
Athyros, V. G., Kakafika A. I., Papageorgiou A. A., Tziomalos K., Skaperdas A., Pagourelias E., et al. (2007).  Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients.. Lipids. 42(11), 999-1009.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2010).  Statin-fibrate combination for mixed dyslipidaemia: a limited option?. Curr Med Res Opin. 26(9), 2137-40.
Athyros, V. G., Tziomalos K., & Karagiannis A. (2015).  Editorial: Statins or Fibrates for the Primary Prevention of Stroke in the Elderly. Faith Makes Some Things Achievable, But Not AII.. Curr Vasc Pharmacol. 13(6), 696-8.
Athyros, V. G., Mikhailidis D. P., Didangelos T. P., Giouleme O. I., Liberopoulos E. N., Karagiannis A., et al. (2006).  Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.. Curr Med Res Opin. 22(5), 873-83.
Athyros, V. G., Tziomalos K., Karagiannis A., Wierzbicki A. S., & Mikhailidis D. P. (2010).  Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association?. Curr Opin Cardiol. 25(4), 406-10.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2009).  The JUPITER trial results boost the evidence for the use of hsCRP as a treatment target and as part of the assessment of vascular risk: time for new guidelines?. Hellenic J Cardiol. 50(2), 89-91.
Athyros, V. G., & Mikhailidis D. P. (2014).  Uric acid, chronic kidney disease and type 2 diabetes: a cluster of vascular risk factors.. J Diabetes Complications. 28(2), 122-3.
Athyros, V. G., Ganotakis E. S., Tziomalos K., Papageorgiou A. A., Anagnostis P., Griva T., et al. (2010).  Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population.. Curr Med Res Opin. 26(3), 713-9.
Athyros, V. G., Gossios T. D., Tziomalos K., Florentin M., Karagiannis A., & Mikhailidis D. P. (2011).  Is there an additional benefit from coronary revascularization in diabetic patients with acute coronary syndromes or stable angina who are already on optimal medical treatment?. Arch Med Sci. 7(6), 1067-75.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές